Intended for healthcare professionals

What if we could cut skin cancer death rates in half?

MedX
Skin cancer kills approximately 2,500 people every year in the UK (see Box 1). Moreover, more men than women die of malignant melanoma; men aged 30–34 have a 1.5 fold higher risk of dying compared to similarly aged women, and this rate increases to 1.7 fold for those aged between 55 to 64 years. There is a considerable economic burden on the NHS for treating malignant melanoma; costs were estimated to be over £105 million in 2008 – 2009 and are projected to exceed £180 million by 2020.
Dermatology in practice 2017; 23(1): 10–12
To continue reading this article, please sign in or register.

Dermatology in practice was previously supported by Wyeth from 2008 to 2010, by Wyeth and Serono in 2007, by Wyeth and Shire from 2005 to 2006, by Medlock Medical in 2004 and by SSL International from 2001 to 2003.

The data, opinions and statements appearing in the articles herein are those of the contributor(s) concerned; they are not necessarily endorsed by the publisher, Editor or Editorial Board. Accordingly the publisher, Editor and Editorial Board and their respective employees, officers and agents accept no liability for the consequences of any such inaccurate or misleading data, opinion or statement.

The title Dermatology in practice is the property of Hayward Medical Publishing and PMGroup Worldwide Ltd and, together with the content, is bound by copyright. Copyright © 2021 PMGroup Worldwide Ltd. All rights reserved. The information contained on the site may not be reproduced, distributed or published, in whole or in part, in any form without the permission of the publishers. All correspondence should be addressed to:

ISSN 0262-5504 (Print) ISSN 2049-8446 (Online)